Article content

TORONTO — Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI), (the “Company” or “Organigram”), Canada’s #1 cannabis company by market share and a growing global cannabis platform following its acquisition of Sanity Group GmbH (“Sanity”), today provided a business update highlighting initial operating performance from Sanity, continued strength in its Canadian business, and upcoming investor engagement.

Article content

“The first quarter following the acquisition of Sanity marks an important milestone for Organigram as we will begin reporting the financial contribution from our international business,” said James Yamanaka, Chief Executive Officer. “Sanity’s initial performance has been consistent with our expectations at the time of acquisition, while our Canadian business continues to demonstrate resilience through market leadership, improving category trends and disciplined execution. We look forward to providing investors with our first full quarter of consolidated financial results in August and discussing our longer-term strategy during our investor session in September.”

Article content

Article content

Article content

Sanity Group Performance¹

Article content

Article content

The Company is providing investors with an initial update on Sanity’s operating performance following the completion of the acquisition in April 2026.

Article content

Since the closing of the acquisition on April 15, 2026, Sanity has maintained an average market share of approximately 10% in Germany and has performed in line with the revenue expectations established at the time of acquisition, supporting management’s confidence in the long-term opportunity within Germany’s growing medical cannabis market.

Article content

The Company also notes that recently announced regulatory changes in Germany² regarding reimbursement eligibility for medical cannabis are not expected to have a material impact on Sanity’s business, as reimbursement-based sales represent approximately 1% of Sanity’s total revenue.

Article content

Canadian Market Share

Article content

Organigram continues to maintain leading positions across Canada’s largest cannabis categories, including:

Article content

Article content

Together, these categories represent more than 86% of total Canadian recreational cannabis retail sales.

Article content

The Company also recorded significant year-over-year market share gains in beverages (+3.1 percentage points) and concentrates (+3.3 percentage points).

Article content

During June, Organigram stabilized the vape market share declines experienced earlier in Q2 Fiscal 2026, with all-in one vape share improving approximately 1 percentage point compared to the previous month. Distribution of the Company’s new all-in-one vape portfolio has now expanded to every Canadian province except Nova Scotia and Quebec.

Article content

Similarly, both pre-roll and infused pre-roll market share improved sequentially during June, reflecting operational improvements implemented during Q2 Fiscal 2026.

Article content

At the end of June, Organigram held 11.1% Canadian recreational cannabis market share, down 0.4 percentage points year-over-year. Sequentially, the Company’s market share improved 100 basis points versus May. Sequential market share improvements in June across vape and pre-roll categories provide positive early indicators that the commercial and operational initiatives put in place in Q2 fiscal 2026 are beginning to positively impact performance.

Article content

The Company continues optimizing its SKU count to focus its resources on delivering higher SKU-level performance and delivering operational efficiencies across the board.

Article content

Article content

Q3 Fiscal 2026 Reporting & Digital Investor Session

Article content

Organigram expects to report its Q3 Fiscal 2026 financial results on or about August 11, 2026, representing the first quarter to include consolidated financial results from both Organigram and Sanity.

Article content

Additional details regarding the quarterly earnings conference call will be announced in the coming weeks.

Article content

The Company also intends to host its second Digital Investor Session in late September 2026.

Article content

The session will provide investors with Organigram’s most comprehensive strategic update since the Sanity acquisition and is expected to include:

Article content

Article content

Additional details, including registration information and instructions for submitting questions, will be provided in advance of the event.

Article content

Article content

About Organigram

Article content

Organigram Global Inc. is a NASDAQ Global Select Market and TSX listed company whose wholly owned subsidiaries include Organigram Inc., a licensed cultivator and processor. Through its acquisition of Sanity Group, Organigram participates in the German medical cannabis market and other emerging markets within Europe.

Article content

Organigram is focused on producing high-quality cannabis for adult consumers, as well as extending the Company’s global footprint. Organigram has also developed and acquired a portfolio of cannabis brands, including Edison, Big Bag O’ Buds, SHRED, Monjour, Tremblant, Collective Project, Trailblazer, BOXHOT and DEBUNK. Through its acquisition of Sanity Group, Organigram’s European brands include Vayamed, avaay, ZOIKS, Endosane, VAAY, and Grashaus. Organigram operates facilities in Moncton, New Brunswick and Lac Supérieur, Quebec, with a dedicated edibles manufacturing facility in Winnipeg, Manitoba. The Company also operates two additional cannabis processing facilities in Southwestern Ontario; one in Aylmer and the other in London. The facility in Aylmer houses best-in-class extraction capabilities, and is optimized for formulation refinement, post-processing of minor cannabinoids, and infused pre-roll production. The facility in London will be optimized for labelling, packaging, and national fulfillment. The Company is regulated by Health Canada under the Cannabis Act and the Cannabis Regulations.